Morgan Stanley’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-16,614
| Closed | -$661K | – | 6686 |
|
|
2016
Q3 | $661K | Buy |
16,614
+15,614
| +1,561% | +$174K | ﹤0.01% | 4344 |
|
|
2016
Q2 | $13K | Sell |
1,000
-12,729
| -93% | -$119K | ﹤0.01% | 6001 |
|
|
2016
Q1 | $112K | Buy |
13,729
+5,110
| +59% | +$38.5K | ﹤0.01% | 5267 |
|
|
2015
Q4 | $87K | Sell |
8,619
-97,982
| -92% | -$1.02M | ﹤0.01% | 5481 |
|
|
2015
Q3 | $1.03M | Buy |
106,601
+60,284
| +130% | +$846K | ﹤0.01% | 4081 |
|
|
2015
Q2 | $799K | Buy |
46,317
+46,185
| +34,989% | +$675K | ﹤0.01% | 4369 |
|
|
2015
Q1 | $1K | Sell |
132
-4,361
| -97% | -$46.8K | ﹤0.01% | 6515 |
|
|
2014
Q4 | $37K | Buy |
4,493
+4,090
| +1,015% | +$35.2K | ﹤0.01% | 5897 |
|
|
2014
Q3 | $4K | Sell |
403
-1,159
| -74% | -$22.9K | ﹤0.01% | 6377 |
|
|
2014
Q2 | $96K | Buy |
1,562
+1,233
| +375% | +$75K | ﹤0.01% | 5519 |
|
|
2014
Q1 | $37K | Sell |
329
-3,229
| -91% | -$227K | ﹤0.01% | 5816 |
|
|
2013
Q4 | $153K | Sell |
3,558
-4,978
| -58% | -$234K | ﹤0.01% | 5160 |
|
|
2013
Q3 | $514K | Buy |
+8,536
| New | +$447K | ﹤0.01% | 4309 |
|
Morgan Stanley's TBRA Position: Q4 2016 in Review
Morgan Stanley sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2016, closing a stake of 16,614 shares — an estimated $661K sold.
Morgan Stanley first reported a position in TBRA in Q3 2013 and held it in 13 quarters. The position peaked at $1.03M in Q3 2015. 0 funds tracked by Wall St. Rank hold TBRA as of Q4 2016.
- Morgan Stanley reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
- Morgan Stanley sold 16,614 Tobira Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $661K.
- Morgan Stanley first reported a position in Tobira Therapeutics, Inc. Common Stock in Q3 2013 and held it in 13 quarters.
- Morgan Stanley's Tobira Therapeutics, Inc. Common Stock position peaked at $1.03M in Q3 2015.
- 0 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2016.
Based on Morgan Stanley's 13F filing for Q4 2016, filed 13 Feb 2017.